{
  "schema_version": "3.1.1-production",
  "doc_id": "CT-19897",
  "evaluation_id": "CT-19897",
  "extraction_date": "2022-07-20",
  "extraction_metadata": {
    "processing_version": "auto",
    "extraction_date": "2022-07-20",
    "parser": "auto",
    "annotateur_default": "auto",
    "niveau_confiance_default": 4,
    "source_files": {
      "F1": {
        "file_name": "ct_CT-19897_XIGDUO_PIS_Avisdef_CT19897.pdf",
        "type": "CT",
        "page_count": 3
      }
    }
  },
  "template_detecte": "CT_modern",
  "section_taxonomy_version": "1.0",
  "SegmentIndex": [
    {
      "segment_id": "CT-19897_seg_01",
      "section_label_normalise": "SYNTHESE_DE_L_AVIS",
      "section_label_brut": "L’essentiel",
      "template_detecte": "CT_modern",
      "page_start": 1,
      "page_end": 2,
      "char_start": 0,
      "char_end": 500,
      "heading_text": "L’essentiel",
      "expected_fields": [
        "indication",
        "secteurs"
      ],
      "routing_hint": "summary",
      "label_confidence": 0.9
    },
    {
      "segment_id": "CT-19897_seg_02",
      "section_label_normalise": "INFORMATIONS_ADMINISTRATIVES",
      "section_label_brut": "Contexte",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 2,
      "char_start": 0,
      "char_end": 300,
      "heading_text": "Contexte",
      "expected_fields": [
        "demande",
        "alternatives"
      ],
      "routing_hint": "context",
      "label_confidence": 0.9
    },
    {
      "segment_id": "CT-19897_seg_03",
      "section_label_normalise": "INFORMATIONS_ADMINISTRATIVES",
      "section_label_brut": "Conclusions de la Commission",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 3,
      "char_start": 0,
      "char_end": 200,
      "heading_text": "Conclusions de la Commission",
      "expected_fields": [
        "avis",
        "decision"
      ],
      "routing_hint": "conclusions",
      "label_confidence": 0.9
    },
    {
      "segment_id": "CT-19897_seg_04",
      "section_label_normalise": "INFORMATIONS_ADMINISTRATIVES",
      "section_label_brut": "Informations administratives et réglementaires",
      "template_detecte": "CT_modern",
      "page_start": 3,
      "page_end": 3,
      "char_start": 0,
      "char_end": 400,
      "heading_text": "Informations administratives et réglementaires",
      "expected_fields": [
        "date_evaluation",
        "presentation",
        "demandeur",
        "AMM",
        "code_ATC"
      ],
      "routing_hint": "admin",
      "label_confidence": 0.9
    }
  ],
  "Identifiants_Produits_Liaison": [
    {
      "produit_id": "CT-19897_prod_01",
      "evaluation_id": "CT-19897",
      "nom_commercial": "XIGDUO",
      "dci": "dapagliflozine/metformine",
      "code_CIP13": "34009 278 865 3 9",
      "forme_pharmaceutique": "comprimé pelliculé",
      "dosage": "5 mg/1000 mg",
      "boite": "Boîte de 56",
      "titulaire_AMM": "ASTRAZENECA",
      "code_ATC": "A10BD15",
      "evidence": [
        {
          "field": "code_CIP13",
          "f": "F1",
          "p": 3,
          "s": "CT-19897",
          "t": "CIP : 34 009 278 865 3 9",
          "m": "manual",
          "c": 0.95
        }
      ]
    }
  ],
  "Evaluations_HAS": [
    {
      "evaluation_id": "CT-19897",
      "Num_avis": "CT-19897",
      "produit_nom": "XIGDUO",
      "dci": "dapagliflozine/metformine",
      "type_avis": "Arrêt du remboursement de certaines présentations en vue d’un arrêt de commercialisation",
      "type_avis_enum": "Réévaluation",
      "forme": "comprimé pelliculé",
      "dosage": "5 mg/1000 mg",
      "indication": "Chez les adultes âgés de 18 ans et plus atteints de diabète de type 2, en complément du régime alimentaire et de l'exercice physique, pour améliorer le contrôle glycémique : chez les patients contrôlés de manière inadéquate par la metformine seule à la dose maximale tolérée ; en association avec un sulfamide hypoglycémiant, chez les patients dont le contrôle glycémique est insuffisant à la dose maximale de metformine associée à un sulfamide hypoglycémiant ; en association avec l'insuline, chez les patients dont le contrôle glycémique est insuffisant à la dose maximale de metformine associée à l'insuline ; chez les patients déjà traités par l'association dapagliflozine et metformine sous la forme de comprimés séparés.",
      "classe_ATC": "A10BD15",
      "pathologie": "Diabète de type 2",
      "maladie_rare": false,
      "ligne_traitement": "Non renseigné",
      "ligne_traitement_enum": null,
      "cim10_principal": "Non renseigné",
      "cim10_secondaires": [],
      "libelle_cim10": "Non renseigné",
      "source_cim10": "Non renseigné",
      "aire_therapeutique_niveau_1": "Endocrinologie",
      "aire_therapeutique_niveau_2": "Diabète",
      "aire_therapeutique_niveau_3": "Diabète de type 2",
      "source_aire_therapeutique": "Déduit ATC A10BD15",
      "design_etude": "Non renseigné",
      "niveau_preuve_brut": "Non renseigné",
      "niveau_preuve_interprete": "Non renseigné",
      "besoin_medical_brut": "Non renseigné",
      "besoin_medical_interprete": "Non renseigné",
      "pathologie_categorie_enum": "Endocrinologie",
      "age_restriction_flag": true,
      "age_restriction_detail": "Adultes âgés de 18 ans et plus",
      "biomarqueur_requis": "Aucun",
      "design_enum": "Non renseigné",
      "caractere_innovant_reconnu": null,
      "perte_de_chance_citee": null,
      "historique_Has_produit": "Non renseigné",
      "historique_ASMR_comparateurs": "Non renseigné",
      "concurrence_therapeutique_recente": "Non renseigné",
      "vote_unanimite": null,
      "nb_votants": null,
      "nb_voix_pour": null,
      "nb_voix_contre": null,
      "nb_abstentions": null,
      "date_evaluation": "2022-07-20",
      "transcription_textuelle": "Non renseigné",
      "extraits_arguments": [
        "Présentation non commercialisée, donc radiation favorable"
      ],
      "gravite_patho": "Non renseigné",
      "gravite_patho_enum": [],
      "type_population_cible": "Adultes âgés de 18 ans et plus atteints de diabète de type 2",
      "pertinence_concurrence_therapeutique": "Non renseigné",
      "evidence": [
        {
          "field": "indication",
          "f": "F1",
          "p": 1,
          "s": "CT-19897",
          "t": "Chez les adultes âgés de 18 ans et plus atteints de diabète de type 2...",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "classe_ATC",
          "f": "F1",
          "p": 3,
          "s": "CT-19897",
          "t": "Code ATC A10BD15",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    }
  ],
  "Essais_Cliniques": [],
  "Critères_Jugement": [],
  "Tolérance": {
    "tolerance_id": "CT-19897_tol",
    "evaluation_id": "CT-19897",
    "essai_id": null,
    "ae_total_pct": null,
    "ae_total_pct_comparateur": null,
    "sae_pct": null,
    "sae_pct_comparateur": null,
    "discontinuations_ae_pct": null,
    "discontinuations_ae_pct_comparateur": null,
    "deaths_ae_n": null,
    "deaths_ae_n_comparateur": null,
    "sae_data_available": false,
    "sae_superieur_comparateur": null,
    "deaths_reported": false,
    "EI_graves_detailles": [],
    "EI_frequents_detailles": [],
    "ei_grade_max": "Non renseigné",
    "deces_detailles": [],
    "signal_securite_flag": false,
    "signal_securite_detailles": [],
    "signal_ansm_flag": false,
    "EI_graves": "Non renseigné",
    "EI_frequents": "Non renseigné",
    "deces": "Non renseigné",
    "signal_securite": "Non renseigné",
    "evidence": [],
    "_meta": {}
  },
  "Comparateurs_Essai": [],
  "Comparateurs_HAS": [
    {
      "comparateur_id": "CT-19897_compHAS_01",
      "evaluation_id": "CT-19897",
      "nom_comparateur_HAS": "XIGDUO 5 mg/1000 mg, boîte de 60 comprimés pelliculés",
      "type_comparateur": "Traitement actif",
      "comparateur_standard_soin": "Alternative restant disponible",
      "famille_comparateur": "Hypoglycémiant oral",
      "evidence": [
        {
          "field": "nom_comparateur_HAS",
          "f": "F1",
          "p": 2,
          "s": "CT-19897",
          "t": "deux autres présentations en boîte de 60 comprimés pelliculés de XIGDUO 5 mg/1000 mg",
          "m": "manual",
          "c": 0.9
        }
      ],
      "_meta": {}
    }
  ],
  "Arguments_Decisionnels": [
    {
      "argument_id": "CT-19897_arg_CT_01",
      "evaluation_id": "CT-19897",
      "source_argument": "CT",
      "categorie_argument": "Procédural",
      "direction_argument": "Favorable",
      "description": "La présentation (boîte de 56 comprimés) n'a jamais été commercialisée, justifiant la radiation des listes de remboursement.",
      "extrait_textuel": "au motif que celle-ci n’a jamais été commercialisée",
      "importance_argument": "Majeur",
      "niveau_incertitude": "Faible",
      "page_source": "Page 2",
      "section_source": "Contexte",
      "intervenant": null,
      "moment_debat": null,
      "impact_decision": "Contributeur_majeur",
      "evidence": [
        {
          "field": "extrait_textuel",
          "f": "F1",
          "p": 2,
          "s": "CT-19897",
          "t": "au motif que celle-ci n’a jamais été commercialisée",
          "m": "manual",
          "c": 0.95
        }
      ]
    }
  ],
  "Données_Contexte": {
    "contexte_id": "CT-19897_ctx",
    "evaluation_id": "CT-19897",
    "ISP": "Non renseigné",
    "acces_precoce": "Aucun",
    "date_debut_acces_precoce": "Non renseigné",
    "date_fin_acces_precoce": "Non renseigné",
    "duree_acces_precoce_mois": null,
    "nombre_patients_acces_precoce": null,
    "conditions_arret_acces_precoce": "Non renseigné",
    "ISP_flag": false,
    "ISP_categorie": "Pas_ISP",
    "type_acces_precoce_enum": "Aucun",
    "statut_reglementaire_ema": "AMM_standard",
    "date_AMM_ema": "2014-01-16",
    "date_avis_chmp": "Non renseigné",
    "innovation_therapeutique_ema": null,
    "designation_orpheline_ema": null,
    "prime_ema": null,
    "obligations_post_amm": [],
    "echeance_reexamen_amm": "Non renseigné",
    "nb_obligations_post_amm": null,
    "evaluation_internationale": "Non renseigné",
    "pays_evaluations": [],
    "decisions_internationales": [],
    "nb_decisions_internationales": null,
    "RDCR": "Non renseigné",
    "RDCR_num": null,
    "RDCR_intervalle": null,
    "RDCR_vs_seuil": "Non renseigné",
    "model_type": "Non renseigné",
    "perspective": "Non renseigné",
    "horizon_annees": null,
    "horizon_justification": "Non renseigné",
    "discount_rate_costs": null,
    "discount_rate_qalys": null,
    "DSA_flag": null,
    "PSA_flag": null,
    "scenario_analyses": [],
    "major_reserves": [],
    "nb_reserves_majeures": null,
    "impact_budgetaire_prevu": "Non renseigné",
    "impact_budgetaire_annee_1": null,
    "impact_budgetaire_annee_5": null,
    "impact_budgetaire_horizon": null,
    "hypothese_population_cible": null,
    "hypothese_penetration_marche_pct": null,
    "reserves_impact_budgetaire": [],
    "reserves_majeures": null,
    "population_cible_france": "Non renseigné",
    "population_cible_nombre": null,
    "population_cible_intervalle": null,
    "source_estimation_population": "Non renseigné",
    "incertitude_population": "Non renseigné",
    "population_cible_mediane": null,
    "suivi_post_inscription": false,
    "nature_suivi_post_inscription": "Non renseigné",
    "delai_suivi_mois": null,
    "delai_suivi_justification": "Non renseigné",
    "conditions_suivi": "Non renseigné",
    "echeance_suivi": "Non renseigné",
    "impact_si_non_realise": "Non précisé",
    "delai_soumission_dossier": "Non renseigné",
    "delai_complement_demande": null,
    "dates_complement_demande": [],
    "delai_audition": null,
    "date_audition": "Non renseigné",
    "nb_total_reserves": null,
    "nb_total_reserves_mineures": null,
    "nb_totales_reserves_importantes": null,
    "nb_totales_reserves_majeures": null,
    "SMR_avant_audition_enum": "Non_renseigné",
    "SMR_apres_audition_enum": "Non_renseigné",
    "ASMR_avant_audition_enum": "Non_renseigné",
    "ASMR_après_audition_enum": "Non_renseigné",
    "type_critère_justification": "Non renseigné",
    "valeur_critère": "Non renseigné",
    "impact_décision": "Non renseigné",
    "estimation_mesure_impact": "Non renseigné",
    "evidence": [
      {
        "field": "date_AMM_ema",
        "f": "F1",
        "p": 3,
        "s": "CT-19897",
        "t": "Date initiale (procédure d’octroi) : 16 janvier 2014",
        "m": "manual",
        "c": 0.95
      }
    ],
    "_meta": {}
  },
  "Données_Textuelles": {
    "evaluation_id": "CT-19897",
    "texte_brut": "Non renseigné",
    "embedding": null
  },
  "SMR_ASMR_Par_Indication": [
    {
      "smr_asmr_id": "CT-19897_smrasmr_01",
      "evaluation_id": "CT-19897",
      "indication_precise": "Diabète de type 2 chez les adultes âgés de 18 ans et plus",
      "smr": "Non renseigné",
      "asmr": "Non renseigné",
      "smr_revendique": "Non renseigné",
      "asmr_revendique": "Non renseigné",
      "justification_decisionnelle": "Avis favorable à la radiation car présentation non commercialisée",
      "population_cible_indication": "Adultes âgés de 18 ans et plus atteints de diabète de type 2",
      "ligne_traitement_indication": "Non renseigné",
      "comparateurs_references_indication": "XIGDUO autres présentations",
      "comparateur_id_HAS": "CT-19897_compHAS_01",
      "indication_structuree": {
        "ligne_traitement": "Non renseigné",
        "biomarqueur": "Aucun",
        "stade": "Non renseigné",
        "population_age": "Adultes ≥18 ans"
      },
      "gain_survie_cite": null,
      "qol_cite": null,
      "tolerance_acceptable": null,
      "evidence_robustesse": "Non renseigné",
      "asmr_revendique_enum": "Non_renseigné",
      "evidence": [],
      "_meta": {}
    }
  ],
  "Posologie_Par_Indication": [],
  "Timeline_Evenements": [
    {
      "event_id": "CT-19897_event_CT_01",
      "evaluation_id": "CT-19897",
      "event_type": "ADOPTION_CT",
      "event_date": "2022-07-20",
      "detail_brut": "Adopté par la Commission de la transparence le 20 juillet 2022",
      "source_doc": "F1",
      "detail_type_specifique": "Non renseigné",
      "acteurs_impliques": [
        "Commission de la transparence"
      ],
      "duree_evenement_jours": null,
      "reference_externe": "Non renseigné",
      "delai_amm_ct_jours": null,
      "delai_ct_jo_jours": null,
      "evidence": [
        {
          "field": "event_date",
          "f": "F1",
          "p": 1,
          "s": "CT-19897",
          "t": "Adopté par la Commission de la transparence le 20 juillet 2022",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    }
  ],
  "Timeline_Delais": {
    "evaluation_id": "CT-19897",
    "delai_eval_depuis_chmp_jours": null,
    "delai_eval_depuis_amm_ema_jours": null,
    "delai_eval_depuis_transcription_jours": null,
    "delai_eval_depuis_evenement_initial_jours": null,
    "nb_clockstops_presumes": 0,
    "delai_total_clockstops_jours": null,
    "clockstops_details": [],
    "delai_eval_flag_incomplet": false,
    "complement_demande_mentionne": false,
    "audition_realisee": false,
    "evidence": [],
    "_meta": {}
  },
  "Features_Modele": {
    "evaluation_id": "CT-19897",
    "is_orphan": false,
    "classe_ATC_l2": "A10B",
    "aire_therapeutique": "Endocrinologie",
    "type_avis_enum": "Réévaluation",
    "innovation_reconnue": null,
    "perte_de_chance_citee": null,
    "ligne_traitement_num": null,
    "is_rct": false,
    "n_essais": 0,
    "n_rct": 0,
    "presence_qol": false,
    "effet_principal_magnitude_num": null,
    "critere_principal_dur": false,
    "suivi_median_mois_max": null,
    "sae_pct_num": null,
    "discontinuations_pct_num": null,
    "critere_principal_description": "Non renseigné",
    "p_value_log10": null,
    "ceesp_present": false,
    "rdcr_num": null,
    "rdcr_log": null,
    "impact_budget_cat": "Non renseigné",
    "reserves_majeures": null,
    "nb_reserves_majeures": null,
    "vote_unanimite": null,
    "nb_votants": null,
    "voix_pour_pct": null,
    "association_patient_intervenue": null,
    "comparateur_placebo": false,
    "comparateur_soc": false,
    "nb_clockstops": 0,
    "annee_ct": 2022,
    "trimestre_ct": "Q3",
    "template_ere": "CT_modern",
    "missingness_indicators": "Non renseigné",
    "_meta": {}
  },
  "Relations": [],
  "Annotation_View": []
}